A new treatment to help manage pain crises in sickle cell disease at home
A novel glycan-based selectin and complement inhibitor for at-home disease-modifying rescue of pain crisis in sickle cell disease
This study is testing a new treatment called IHP-102 for people with sickle cell disease who have painful episodes, aiming to help them manage their pain better at home without relying so much on opioids.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ihp Therapeutics, INC. NIH-funded |
| Lab location | 1 site (San Carlos, UNITED STATES) |
| Project ID | NIH-10785873 on NIH RePORTER |
What this research studies
This research focuses on developing a novel treatment called IHP-102 for patients with sickle cell disease (SCD) who experience painful vaso-occlusive events (VOE). The treatment aims to modify the disease process rather than just mask the pain, which is currently managed with opioids. By targeting multiple underlying mechanisms of pain, IHP-102 empowers patients to manage their pain crises at home, potentially reducing reliance on opioids and improving their quality of life. The approach is designed to be accessible and effective for individuals suffering from SCD.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults with sickle cell disease who experience frequent pain crises.
Not a fit: Patients who do not have sickle cell disease or those who do not experience vaso-occlusive events may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option for managing pain crises in sickle cell disease, improving patient outcomes and quality of life.
How similar studies have performed: While there have been various approaches to managing pain in sickle cell disease, the specific glycan-based therapy being developed in this research is novel and has not been extensively tested in this context.
Where this research is happening
San Carlos, UNITED STATES
- Ihp Therapeutics, INC. — San Carlos, United States (Active)
Researchers
- Principal investigator: John Paderi, John Paderi John Paderi — Ihp Therapeutics, INC.
- Study coordinator: John Paderi, John Paderi John Paderi
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.